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Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced
non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors
and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described
progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter
Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Re-
sults: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3–13.3) for
T790M+ and 6.0 months (95% CI: 4.9–7.2) for T790M- patients, respectively. Median overall survival was
20.7 months (95% CI: 18.9–28.4) for T790M+ and 10.6 months (95% CI: 8.6–23.6) for T790M- patients, re-
spectively. The T790M mutation correlated with absence of new sites of disease. After progression, most
T790M+ patients continued osimertinib, whereas most T790M- patients received a different treatment
line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progres-
sion pattern for T790M+ was suggested.
Lay abstract: Osimertinib is an oral drug that inhibits the growth of non-small-cell lung cancer (NSCLC) tu-
mors with a specific mutation in EGFR. Osimertinib is given to patients with advanced EGFR-mutant NSCLC
as initial therapy or after the failure of prior first- or second-generation tyrosine kinase inhibitors in pa-
tients who develop the EGFR T790M resistance mutation. Real-world data about the efficacy of EGFR-
mutant NSCLC patients receiving osimertinib are needed to confirm the findings of large randomized
clinical trials. Most real-world studies have investigated outcomes in Asian populations. This study aims
to describe outcomes in EGFR T790M-positive patients receiving osimertinib after the failure of first- or
second-generation tyrosine kinase inhibitors, compared with T790M-negative patients receiving a sys-
temic treatment, in a Caucasian population. In addition, the study aims to describe how the disease spreads
once it starts progressing again and any subsequent treatment lines. 167 patients were included. The re-
sults of this study suggest that EGFR T790M-positive patients receiving osimertinib as second- or further-
line treatment had better outcomes and a more limited progression compared with T790M-negative cases.
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Lung cancer is the leading cause of cancer-related death [1]. In the Caucasian population, EGFR activating mutations
are found in about 15% of advanced non-small-cell lung cancer (aNSCLC) patients [2,3]. The most frequent are
exon 19 in-frame deletions (50%) and exon 21 L858R point mutation (40%) [4,5]. Several Phase III clinical trials
have demonstrated the superior efficacy of first- and second-generation EGFR tyrosine kinase inhibitors (1–2gen
TKIs) compared with first-line platinum-based chemotherapy in this subpopulation [6–12].
After about 9–15 months of 1–2gen TKI treatment, acquired resistance occurs, causing disease progression. The
most common mechanism of acquired resistance is the EGFR exon 20 T790M mutation, detectable in about 50%
of rebiopsy samples [13,14].
Osimertinib, a third-generation EGFR TKI, targets activating mutations as well as the T790M mutation. This
compound irreversibly binds to the C797 residue in the EGFR mutant protein ATP-binding pocket, sparing
wild-type EGFR. The Phase III AURA3 trial compared osimertinib with platinum–pemetrexed chemotherapy in
previously treated, EGFR acquired T790M mutation-positive (T790M+) aNSCLC patients, showing a superior
median progression-free survival (mPFS) compared with chemotherapy (10.1 vs 4.4 months; hazard ratio [HR]:
0.30, 95% CI: 0.23–0.41; p < 0.001), as well as a higher overall response rate (ORR) for osimertinib (71%
vs 31%) [15]. Osimertinib was associated with a better safety profile and lower rate of adverse events leading to
permanent discontinuation than platinum–pemetrexed [15]. CNS ORR was 70% with osimertinib and 31% with
chemotherapy [16]. These results led to the US FDA and the EMA approval of osimertinib for acquired EGFR
T790M+ aNSCLC patients progressing on or after 1–2gen TKIs. In the AURA3 trial, median overall survival
(mOS) was not significantly different between the osimertinib arm and chemotherapy (26.8 vs 22.5 months), likely
due to a high crossover rate (71%) [17].
More recently, the Phase III FLAURA trial compared standard first-line EGFR TKIs (gefitinib or erlotinib) with
osimertinib in previously untreated aNSCLC patients with EGFR exon 19 deletion or L858R mutation. FLAURA
reported prolonged mPFS in patients treated with first-line osimertinib (18.9 vs 10.2 months; HR: 0.46; 95% CI:
0.37–0.57; p < 0.001) compared with those receiving gefitinib or erlotinib [18]. Osimertinib was also associated with
a lower rate of grade ≥3 adverse events compared with gefitinib or erlotinib (34% vs 45%) [18]. Thus osimertinib
received approval as first-line therapy for patients with EGFR-mutant aNSCLC, regardless of T790M status. CNS
ORR in FLAURA was superior for patients treated with osimertinib compared with those receiving gefitinib or
erlotinib (91% vs 68%) [19]. FLAURA overall survival (OS) results were finally published, confirming the superior
efficacy of first-line osimertinib compared with gefitinib or erlotinib (mOS 38.6 vs 31.8 months; HR: 0.80; 95%
CI: 0.64–1.00; p = 0.046), with a crossover rate of 31% [20].
Platinum-based chemotherapy is currently the standard of care in patients progressing to 1–2gen TKIs in
T790M-negative (T790M-) patients and in patients experiencing osimertinib failure [21]. The use of osimertinib
as front-line therapy is supported by the FLAURA OS data [20], the real-life observation that up to 30–40% of
patients are not able to receive subsequent therapies after first-line 1–2gen TKIs due to poor performance status
(PS) or death [22–24] and finally the lower toxicity rate produced by osimertinib [20]. Nevertheless, other authors still
claim a role for sequential use of early-generation TKIs followed by osimertinib [25]. Once available, the APPLE
trial result may help to clarify this clinical question [26].
Previous analysis of the pattern of recurrence with early-generation TKIs reported a more aggressive tumor
behavior in T790M+ patients, characterized by more new sites of disease compared with negative cases [27]. Several
studies investigated the efficacy and safety of osimertinib in the real world in T790M+ patients among Asian [28–33],
Caucasian [34–38] and both populations [39–41]. However, few data about progression patterns with osimertinib are
available in T790M+ patients, and previous studies did not include a T790M- control group [30,33,34,36,37]. Real-life
data on progression pattern and on further treatments after the failure of post-TKI treatment could help measure
osimertinib impact on the natural history of EGFR-mutant aNSCLC and improve clinical decision-making.
This study describes the diagnostic–therapeutic pathway of pretreated EGFR-mutant aNSCLC patients receiving
osimertinib or chemotherapy after the failure of 1–2gen TKIs, based on T790M status and according to clinical
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practice. The primary end point was to describe treatment outcomes in terms of ORR, PFS and OS; as secondary
aims, we explored progression patterns and the sequence of further systemic treatments.
Patients & methods
Study design & patients
This is a retrospective observational study collecting a consecutive series of patients referred to six Italian centers
between 2014 and 2018. The main inclusion criteria were: histological diagnosis of aNSCLC (stages IIIB and
IV), presence of EGFR activating mutation, radiological or clinical progression to previous systemic treatment with
1–2gen EGFR TKI (erlotinib, gefitinib or afatinib at standard doses) and the presence of at least one liquid biopsy
or tissue rebiopsy before study entry as confirmation of T790M status.
This study was conducted according to Good Clinical Practice guidelines and the Declaration of Helsinki. An
informed consent form was submitted to living patients, according to Regulation (EU) 2016/679 of the European
Parliament and of the Council on personal data protection. For patients who were dead or lost to follow-up at
the time of study enrollment, we used the Italian Data Protection Authority Authorization 9/2016 on ‘privacy
protective rules for recording clinical data for research and study purposes’.
Baseline patient data collected included: gender, age, smoking status, Charlson comorbidity index, histology,
type of EGFR activating mutation, stage at diagnosis according to the TNM Classification of Malignant Tumors
(eighth edition), baseline metastatic sites, disease-related symptoms, Eastern Co-operative Oncology Group PS,
type of previous 1–2gen TKI and best response to 1–2gen TKI.
Disease progression (PD) was defined as the date of progression upon therapy with osimertinib (for T790M+
patients) or systemic therapy (for T790M- patients). Data recorded at PD were: progression type, type and number
of metastatic sites, disease-related symptoms, subsequent systemic or locoregional treatment, subsequent rebiopsy,
date of treatment discontinuation and date of death or last follow-up.
Patients received second-line treatment with osimertinib (T790M+), 80 mg orally daily, or best investigator
chemotherapy choice (T790M-). In case of baseline T790M negative results, a liquid or tissue biopsy was subse-
quently performed after second-line chemotherapy and, in case of T790M positivity, osimertinib was prescribed
in third or further lines. All patients receiving osimertinib in second or further lines are included in the outcome
analysis within the same T790M+ group.
Tumor assessment was performed through chest and abdomen CT scan with iodine contrast. Brain CT scan with
iodine contrast or nuclear magnetic resonance with gadolinium contrast were performed at baseline and then when
clinically indicated (baseline brain metastases or clinical suspicion of CNS disease spread). Assessment was performed
every 2–3 months as per clinical practice. Response to treatment was classified according to Response Evaluation
Criteria in Solid Tumors version 1.1. Three different progression patterns were defined: solitary (appearance or
growth of one lesion), oligo (progression in up to three lesions in two organs) and systemic progression (progression
in more than three lesions).
PFS was measured as the time between the beginning of osimertinib or second-line chemotherapy and the
radiological and/or clinical evidence of progression, or death; time to treatment failure (TTF) was measured from
the start of osimertinib therapy to treatment cessation for any reason. OS was defined as the time between the
beginning of osimertinib or other systemic therapy until death from any cause.
EGFR mutational analysis
At the time of diagnosis, EGFR mutations were identified in exons 18–21. The analysis was performed on tumor
tissue according to standard clinical practice. At the time of 1–2gen TKI progression, plasma samples were collected
for liquid biopsy to detect the EGFR T790M mutation in circulating tumor DNA. For T790M- patients only, a
second tissue biopsy was achieved if feasible and accepted by the patient.
For analyses on tissue sample, tumor DNA was extracted from formalin-fixed, paraffin-embedded tumor slices
using the QIAamp R© DNA Micro kit or QIAamp R© DNA FFPE kit (Qiagen, Hilden, Germany); DNA sequencing
was carried out with Sanger sequencing, pyrosequencing and PCR-based methods (Easy R© EGFR kit, Diatech
Pharmacogenetics, Jesi, Italy; cobas R© EGFR Mutation Test v2, Roche, Basel, Switzerland), mass spectrometry-
based methods (Sequenom Mass Array, Diatech Pharmacogenetics), or next-generation sequencing (Ion Torrent,
Oncomine™ panel, Thermo Fisher Scientific, MA, USA). For liquid biopsy, cell-free DNA was isolated from
2 ml of plasma using the cobas R© cf-DNA Sample Preparation kit (Roche) and analyzed with the techniques
described above.
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Figure 1. Study design and patients’ flow.
PD: Disease progression; TKI: Tyrosine kinase inhibitor.
Statistical analysis
Statistical analyses were performed using R statistical software (The R Foundation for Statistical Computing,
Vienna, Austria). The chi-square, Mann–Whitney or Fisher exact test and multiple logistic regression were applied
to correlate clinical features with T790M status and the Kaplan–Meier estimator was used to evaluate mPFS,
median TTF (mTTF) and median OS (mOS). The log-rank test and Cox regression model were applied. Statistical
significance was set at p = 0.05.
Results
Study population
One hundred and sixty seven patients were consecutively included across six cancer centers in Italy. Of these, 102
were included in the T790M+ group and 65 in the T790M- group. Among the T790M+ patients, 101 (99%)
received osimertinib, while one (1%) did not receive any further treatment. Among the T790M- patients, 38
(58.5%) received a further line of treatment, while 27 (41.5%) did not (p < 0.001). Median follow-up from the
start of postprogression treatment was 14.1 months (range: 1.0–59.7). Figure 1 depicts patients’ flow and study
design.
Baseline characteristics
Baseline characteristics were similar between the two subgroups defined according to T790M status. Most patients
were female, had never smoked, had stage IV adenocarcinoma and Eastern Co-operative Oncology Group PS 0–1
at diagnosis. EGFR exon 19 deletion (p = 0.025), response to 1–2gen EGFR TKI (p = 0.013) and bone metastases
at diagnosis (p = 0.019) were significantly more frequent in T790M+ patients. Multivariate analysis confirmed that
response to 1–2gen EGFR TKI was associated with T790M mutation (p = 0.046) (Table 1).
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Table 1. Baseline clinical features according to EGFR T790M mutation status.
T790M+ T790M- Univariate analysis Multivariate analysis
n % n % OR 95% CI p-value OR 95% CI p-value
Total patients (n) 101 100 38 100
Sex 0.729 0.340 1.564 0.539
Male 35 34.7 16 42.1
Female 66 65.3 22 57.9
Smoking status 1.319 0.571 3.050 0.569
Smoker 34 33.7 10 26.3
Never smoker 67 66.3 26 68.4
Missing 0 0 2 5.3
Charlson comorbidity index 0.931 0.401 2.164 0.962
6 28 27.7 10 26.3
6 73 72.3 28 73.7
Median age at diagnosis, years
(range)
63 (35–85) 64 (38–82) 0.883
Age at diagnosis, years 0.824 0.389 1.742 0.752
65 58 57.4 20 52.6
≥65 43 42.6 18 47.4
Histology† 2.079 0.443 9.754 0.610
Adenocarcinoma 97 96.0 35 92.2
Others 4 4.0 3 7.8
– Bronchioloalveolar carcinoma 2 2.0 0 0
– Squamous cell carcinoma 2 2.0 1 2.6
– Adenosquamous carcinoma 0 0 1 2.6
– NOS 0 0 1 2.6
Baseline EGFR mutation status‡ 2.545 1.187 5.458 0.025 1.870 0.775 4.514 0.164
Exon 19 deletion 68 67.3 17 44.7
Exon 21 L858R 30 29.7 15 39.5
Others 3 3.0 6 15.8
Stage at diagnosis 2.474 0.707 8.657 0.271
IIIB/IIIC 6 5.9 5 13.2
IV 95 94.1 32 84.2
Missing 0 0 1 2.6
ECOG PS at diagnosis 0.723 0.171 3.054 0.957
0–1 94 93.1 34 89.5
≥2 6 6.0 3 7.9
Missing 1 0.9 1 2.6
First-line TKI treatment§ 0.892 0.405 1.966 0.936
Gefitinib 42 41.6 18 47.4
Erlotinib 20 19.8 4 10.5
Afatinib 32 31.7 13 34.2
Clinical trial 7 6.9 3 7.9
Best response to 1–2 gen TKI¶ 0.351 0.162 0.764 0.013 0.398 0.161 0.982 0.046
CR 2 2.0 0 0
PR 72 71.3 19 50.0
SD 23 22.8 12 31.6
PD 3 3.0 7 18.4
†Adenocarcinoma versus others comparison.
‡Exon 19 deletion versus others comparison.
§Afatinib versus others comparison.
¶SD/PD versus CR/PR comparison.
Statistically significant p-values have been highlighted in bold.
1–2 gen TKI: First- or second-generation tyrosine kinase inhibitor; CR: Complete response; ECOG PS: Eastern Co-operative Oncology Group Performance Status; NOS: Not otherwise
specified; OR: Odds ratio; PD: Progressive disease; PR: Partial response; SD: Stable disease; TKI: Tyrosine kinase inhibitor.
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Table 1. Baseline clinical features according to EGFR T790M mutation status (cont.).
T790M+ T790M- Univariate analysis Multivariate analysis
n % n % OR 95% CI p-value OR 95% CI p-value
Missing 1 0.9 0 0
Brain metastases at diagnosis 1.580 0.546 4.570 0.548
Yes 20 19.8 5 13.2
No 81 80.2 32 84.2
Missing 0 0 1 2.6
Liver metastases at diagnosis 1.242 0.421 3.664 0.898
Yes 16 15.8 5 13.2
No 85 84.2 33 86.8
Bone metastases at diagnosis 3.032 1.264 7.275 0.019 2.132 0.806 5.635 0.127
Yes 46 45.5 8 21.1
No 55 54.5 29 76.3
Missing 0 0 1 2.6
†Adenocarcinoma versus others comparison.
‡Exon 19 deletion versus others comparison.
§Afatinib versus others comparison.
¶SD/PD versus CR/PR comparison.
Statistically significant p-values have been highlighted in bold.
1–2 gen TKI: First- or second-generation tyrosine kinase inhibitor; CR: Complete response; ECOG PS: Eastern Co-operative Oncology Group Performance Status; NOS: Not otherwise
specified; OR: Odds ratio; PD: Progressive disease; PR: Partial response; SD: Stable disease; TKI: Tyrosine kinase inhibitor.
Treatment outcomes
The 101 T790M+ patients received osimertinib, 79 (78.2%) of them as a second-line treatment and the remain-
ing 22 (21.8%) after one or more lines of systemic treatment because of delayed T790M acquisition (Figure 1).
Conversely, the 38 T790M- patients received chemotherapy, of whom 32 (84.2%) were given a platinum combi-
nation and 6 (15.8%) a single-agent chemotherapy (Figure 1).
ORR was higher for T790M+ patients treated with osimertinib compared with patients in the T790M- group
(62.4 vs 47.4%), even though the difference did not attain statistical significance, whereas the disease control rate
(DCR) was similar between the two groups (80.2 vs 76.3%; Supplementary Table 1).
At data cutoff (17 May 2020), 77 of 101 (76.2%) T790M+ patients and 37 of 38 (97.4%) T790M- patients
had a progression event.
The mPFS was 9.8 months (95% CI: 8.3–13.3) for T790M+ and 6.0 months (95% CI: 4.9–7.2) for T790M-
patients (log-rank test p = 0.00017; HR: 0.47; 95% CI: 0.32–0.70; p = 0.0004) (Figure 2A). The mPFS was
similar between patients receiving osimertinib as a second-line therapy or as a further-line treatment (9.4 vs
9.7 months) (Supplementary Figure 1A). At univariate analysis, T790M- status, baseline brain metastases, stable
disease (SD)/progressive disease (PD) as best response to previous TKI and SD/PD as best response to treatment
were associated with a higher risk of progression. Multivariate analysis confirmed that T790M- status, baseline
brain metastases and SD/PD as best response to treatment were significant covariates associated with a higher risk
of progression (Supplementary Table 2).
Osimertinib mTTF was 14.9 months (95% CI: 11.8–20.5) (Figure 2B). For T790M- patients receiving
chemotherapy, TTF was not calculated because treatment beyond progression was not an option.
At data cutoff, 53 of 101 (52.5%) T790M+ patients and 29 of 38 (76.3%) T790M- patients had died.
The mOS was significantly higher in the T790M+ group (20.7 months; 95% CI: 18.9–28.4) compared with
the T790M- group (10.6 months; 95% CI: 8.6–23.6; log-rank test p = 0.014; HR: 0.57; 95% CI: 0.36–0.90; p =
0.02) (Figure 2C).
The mOS was similar between patients receiving osimertinib as a second-line therapy or as a further-line
treatment (20.7 vs 18.0 months; Supplementary Figure 1B).
At univariate analysis, EGFR T790M mutation and baseline EGFR exon 19 deletion were associated with a
lower risk of death, whereas baseline bone metastases, baseline brain metastases and SD/PD as best response to
treatment were significantly associated with a higher risk of death. Multivariate analysis confirmed EGFR T790M
mutation as a positive prognostic factor, with baseline bone metastases, baseline brain metastases and SD/PD as
best response to treatment as significant covariates associated with a higher risk of death (Supplementary Table 3).
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Figure 2. Survival curves for EGFR T790M mutation-positive compared with T790M mutation-negative patients. (A)
Progression-free survival. (B) Time to osimertinib treatment failure. (C) Overall survival.
Progression pattern with osimertinib compared with chemotherapy
We explored the progression pattern with osimertinib in T790M+ compared with chemotherapy in T790M-
patients. In ten cases, complete information about progression pattern was not available.
At univariate analysis, when information on clinical and radiological progression was available (n = 104; T790M+,
n = 71; T790M-, n = 33), the T790M mutation was significantly correlated with the absence of new sites of disease
(p = 0.048). There was a trend toward more frequent liver and bone progression in T790M+ patients and toward
more systemic progression (compared with oligo or isolated progression), thoracic, distant nodes, pleura, brain,
adrenal, soft tissue, peritoneum and pericardium progression in T790M- patients, although these trends did not
reach statistical significance. The correlation between T790M mutation and the presence of new sites of disease
was not confirmed at multivariate analysis (Table 2 & Supplementary Figure 2).
A trend toward new distant nodes, brain, soft tissue, lung, adrenal, pleura and kidney progression was shown
for T790M+ patients, whereas new bone, peritoneum, liver and pericardium progression were more frequent in
T790M- patients, though the difference did not reach statistical significance (Table 2).
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Table 2. Progression pattern with osimertinib or chemotherapy according to EGFR T790M mutation status.
T790M+ T790M- Univariate analysis Multivariate analysis†
n % n % OR 95% CI p-value OR 95% CI p-value
Total patients (n) 71 100 33 100
Type of progression NA NA NA 0.255
Systemic 39 55.0 21 63.6
Oligo 16 22.5 9 27.3
Isolated 16 22.5 3 9.1
Type of progression (systemic vs
oligo and isolated)
0.696 0.298 1.629 0.533
Type of progression (systemic and
oligo vs isolated)
0.344 0.093 1.275 0.168
Progressing sites (n) 0.427 0.177 1.030 0.092
≥3 17 23.9 14 42.4
3 54 76.1 19 57.6
Progression-related symptoms 1.016 0.443 2.328 0.861
Yes 39 54.9 18 54.5
No 32 45.1 15 45.5
Lung progression 0.914 0.404 2.068 0.994
Yes 41 57.7 22 66.7
No 30 42.3 11 33.3
Bone progression 2.020 0.730 5.590 0.257
Yes 22 31.0 6 18.2
No 49 69.0 27 81.8
Brain progression 0.681 0.237 1.953 0.661
Yes 11 15.5 7 21.2
No 60 84.5 26 78.8
Liver progression 1.313 0.510 3.378 0.742
Yes 21 29.6 8 24.2
No 50 70.4 25 75.8
Adrenal progression 0.684 0.109 4.301 0.932
Yes 3 4.2 2 6.1
No 68 95.8 31 93.9
Distant nodes progression 0.636 0.232 1.744 0.537
Yes 12 16.9 8 24.2
No 59 83.1 25 75.8
Soft tissue progression 0.684 0.109 4.301 0.932
Yes 3 4.2 2 6.0
No 68 95.8 31 94.0
Pericardium progression 0.221 0.0193 2.534 0.490
Yes 1 1.4 2 6.0
No 70 98.6 31 94.0
Spleen progression NA NA NA NA
Yes 0 0 0 0
No 71 100 33 100
Kidney progression inf 0 inf 0.693
Yes 1 1.4 0 0
No 70 98.6 33 100
Pleura progression 0.512 0.181 1.449 0.319
Yes 10 14.1 8 24.2
No 61 85.9 25 75.8
†Spleen progression and each single new site of disease variables were not included in multiple logistic regression.
Statistically significant p-values have been highlighted in bold.
inf: Infinite; NA: Not applicable; OR: Odds ratio.
2520 Future Oncol. (2021) 17(19) future science group
Osimertinib real-world data in pretreated non-small-cell lung cancer Research Article
Table 2. Progression pattern with osimertinib or chemotherapy according to EGFR T790M mutation status (cont.).
T790M+ T790M- Univariate analysis Multivariate analysis†
n % n % OR 95% CI p-value OR 95% CI p-value
Peritoneum progression 0.334 0.0835 1.338 0.218
Yes 4 5.6 5 15.2
No 67 94.4 28 84.8
Regional lymph nodes progression 0.565 0.220 1.453 0.346
Yes 14 19.7 10 30.3
No 57 80.3 23 69.7
Data available for new sites of
disease
64 100.0 33 100.0
New sites of disease 0.367 0.163 0.914 0.048 0.315 0.0863 1.153 0.081
Yes 22 34.4 19 58.8
No 42 65.6 14 41.2
New sites of disease (n) 0.357 0.075 1.698 0.224
≥3 3 4.7 4 11.7
3 61 95.3 29 88.2
New lung progression 1.800 0.150 21.569 1.000
Yes 2 9.1 1 5.3
No 20 90.9 18 94.7
New bone progression 0.442 0.090 2.166 0.436
Yes 3 13.6 5 26.3
No 19 86.3 14 73.7
New brain progression 1.406 0.331 5.983 0.727
Yes 6 27.3 4 21.1
No 16 72.7 15 78.9
New liver progression 0.833 0.178 3.911 1.000
Yes 4 18.2 4 21.1
No 18 81.8 15 78.9
New adrenal progression 1.800 0.150 21.596 1.000
Yes 2 9.1 1 5.3
No 20 90.1 18 94.7
New distant nodes progression 2.489 0.542 11.436 0.292
Yes 7 31.8 3 15.8
No 15 68.2 16 84.2
New soft tissue progression 2.842 0.270 29.897 0.610
Yes 3 13.6 1 5.3
No 19 86.4 18 94.7
New pericardium progression 0 0 inf 0.209
Yes 0 0 2 10.5
No 22 100 17 89.5
New spleen progression NA NA NA NA
Yes 0 0 0 0
No 22 100 19 100
New kidney progression inf 0 inf 1.000
Yes 1 4.5 0 0
No 21 95.5 19 100
New pleura progression 1.800 0.150 21.569 1.000
Yes 2 9.1 1 5.3
No 20 90.9 18 94.7
†Spleen progression and each single new site of disease variables were not included in multiple logistic regression.
Statistically significant p-values have been highlighted in bold.
inf: Infinite; NA: Not applicable; OR: Odds ratio.
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Table 2. Progression pattern with osimertinib or chemotherapy according to EGFR T790M mutation status (cont.).
T790M+ T790M- Univariate analysis Multivariate analysis†
n % n % OR 95% CI p-value OR 95% CI p-value
New peritoneum progression 0 0 inf 0.016
Yes 0 0 5 26.3
No 22 100 14 73.7
New regional lymph nodes
progression
0.850 0.108 6.695 1.000
Yes 2 9.1 2 10.5
No 20 90.9 17 89.5
†Spleen progression and each single new site of disease variables were not included in multiple logistic regression.
Statistically significant p-values have been highlighted in bold.
inf: Infinite; NA: Not applicable; OR: Odds ratio.
Table 3. Further systemic and locoregional therapies after osimertinib or chemotherapy according to EGFR T790M
mutation status.
T790M+ Drug T790M- p-value
n % n %
77 100 37 100
Further treatments 0.262†
No further systemic treatment 16 20.8 12 32.4
Patients continuing systemic therapy beyond
progression
33 42.8 0 0
New systemic therapy line 28 36.4 25 67.6
– Carboplatin–pemetrexed 11 39.3 Docetaxel 12 48.0
– Cisplatin–pemetrexed 4 14.3 Nivolumab 5 20.0
– Vinorelbine 3 10.7 Gemcitabine 2 8.0
– Atezolizumab–bevacizumab–carboplatin–
paclitaxel
3 10.7 Docetaxel–nintedanib 2 8.0
– Nivolumab 2 7.1 Atezolizumab 2 8.0
– Carboplatin–paclitaxel 1 3.6 Pemetrexed 1 4.0
– Docetaxel 1 3.6 Pembrolizumab 1 4.0
– Cisplatin–gemcitabine–bevacizumab 1 3.6
– Carboplatin–paclitaxel–bevacizumab 1 3.6
– Missing 1 3.6
Locoregional therapy 0.451
– Yes 30 39.0 11 29.7
– No 47 61.0 26 70.3
†Chi-squared test for yes (therapy beyond progression or new systemic therapy line) versus no.
Further treatments & rebiopsy rate
Of the 77 T790M+ patients whose disease progressed with osimertinib given as second- or later-line therapy, 33
(42.8%) continued the drug beyond progression, 28 patients (36.4%) switched to a new systemic therapy and 16
(20.8%) did not receive any further treatment (Table 3).
Among patients with progression with osimertinib given as second-line treatment (n = 58), 24 (41.4%) continued
osimertinib beyond progression, 23 (39.7%) switched to a new systemic therapy and 11 patients (18.9%) did not
receive any further treatment. Among patients with progression with osimertinib given as third- or further-line
treatment (n = 19), nine (47.4%) continued osimertinib beyond progression, five (26.3%) switched to a new
systemic therapy and five patients (26.3%) did not receive any further treatment. The proportion of patients
receiving no further treatments was similar between the two groups (p = 0.523).
After progression to chemotherapy, 25 of 37 (67.6%) T790M- patients received a further systemic therapy line,
whereas 12 patients (32.4%) did not. Twenty-one of 28 (75%) T790M+ patients received a platinum combination
therapy, while 12 of 25 (48%) T790M- patients received docetaxel (Table 3).
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Figure 3. Number of further systemic
therapy lines for EGFR T790M
mutation-positive patients compared with
T790M-negative patients.
The median number of further systemic treatment lines was one in both groups (Mann–Whitney test; p = 0.794;
Figure 3).
A similar proportion of patients (30 of 77 T790M+ patients [39.0%] vs 11 of 37 T790M- patients [29.7%]; p
= 0.451) received local ablative therapy after progression (Table 3).
Data on rebiopsy after progression with osimertinib or chemotherapy was available in 40 out of 77 T790M+
patients and in 22 out of 37 T790M- patients.
A significantly higher proportion of T790M- patients underwent rebiopsy (9 of 40 [22.5%] T790M+ and 15
of 22 [68.2%] T790M-; p = 0.001). Liquid biopsy was performed in four of nine (44.4%) T790M+ patients and
in eight of 15 (53.4%) T790M- patients. Tissue biopsy was performed in four of nine (44.4%) T790M+ patients
and in two of 15 (13.3%) T790M- patients. One of nine (11.2%) patients in the T790M+ group and five of 15
(33.3%) in the T790M- group underwent both liquid and tissue rebiopsy.
Discussion
This real-world, multicenter study has shown treatment outcomes and progression pattern of pretreated patients
with EGFR mutation-positive NSCLC receiving osimertinib or chemotherapy as second- or further-line systemic
therapy.
The activity of osimertinib in our Caucasian T790M+ population is consistent with the pooled analysis of two
Phase II studies, AURA extension and AURA2, and the Phase III AURA3 trial data (ORR 66–71% and disease
control rate 91–93%) [15,42].
Reported mPFS was 9.9 months in the AURA extension and AURA2 studies pooled analysis, and 10.1 months
in AURA3 for patients treated with osimertinib [15,42]. Similarly, we reported a mPFS of 9.8 months for patients
treated with osimertinib. Conversely, mOS in patients receiving osimertinib in our study (20.7 months) was slightly
shorter than in the experimental arm of AURA3 (26.8 months); this could be related to the higher selection of
patients eligible for the clinical trial, potentially impacting on subsequent treatment lines [15]. The main differences
in patients’ clinical characteristics were related to ethnicity (predominantly Asian in AURA trials) and the proportion
of patients treated with afatinib (31.7% in our population vs 7% in AURA3 and 18% in AURA extension and
AURA2 pooled analysis) [15,42].
Moreover, treatment regimens after disease progression in real life compared with those in randomized trials
may impact survival data. In our analysis, 42.8% of T790M+ patients continued osimertinib beyond progression,
36.4% switched to a new systemic therapy and 20.8% did not receive any further treatment. Likewise, continuing
osimertinib beyond progression was the most common treatment strategy in pivotal trials (73% of patients in the
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pooled AURA Phase II analysis and 64% in AURA3) [15,42]. A higher proportion of patients receiving subsequent
anticancer therapy after osimertinib failure in the Phase II AURA pooled analysis (69%) and AURA3 (59.2%) was
reported compared with our study (36.4%) [15,42]. Again, this could be related to more selective inclusion criteria
in clinical trials.
Other real-world studies have recently reported outcomes and response rates in line with pivotal trials, even
though the added value of our study is the inclusion of a T790M- group [28–32,34–36,38–41,43]. In real-world studies, a
variable rate of patients received a subsequent treatment after osimertinib failure [29,34–37]. The study by Auliac et al.
included only patients aged >80 years and this could explain the lower proportion of patients receiving subsequent
therapies after osimertinib [35], whereas the higher rate reported by Le et al. may be explained by selection bias [40].
As in our experience, after osimertinib, most patients received chemotherapy [34–36], according to guidelines [21].
One study reported immune checkpoint inhibitors as the most frequent therapy after osimertinib, but included
patients from 2011 [40].
Our study showed no statistically significant difference in treatment outcome when osimertinib was prescribed
in different treatment lines. Consistent with our findings, a similar mPFS and mOS was reported for patients
receiving osimertinib as a second, third or further line of treatment in the AURA extension and AURA2 pooled
analysis [42]. Three real-world studies reported no statistically significant difference between outcomes for osimertinib
administered as a second or as a further line of treatment [29,34,35]. On the basis of these observations, it is tempting
to suggest a role of tissue rebiopsy or repeated liquid biopsy in T790M- patients at every disease progression event
in order to detect T790M mutation.
Furthermore, regarding progression pattern, in the pooled analysis of AURA extension and AURA2 trials, 41%
of patients had disease progression with new lesions, whereas in AURA3 this figure was 26% (compared with
45% receiving chemotherapy) [15,42]. Consistent with these findings, we reported that 34% of patients treated with
osimertinib had new sites of disease, defining a population with better disease control and a lower risk of disease
spread with systemic treatment compared with T790M- patients (58.8%). In our records, at univariate analysis
we revealed a significant correlation between T790M mutation and the absence of new sites of disease compared
with the T790M- group.
In several studies investigating progression patterns with osimertinib, progression in T790M+ patients was
characterized by local and oligoprogression compared to systemic progression [30,33,36]. Oligoprogression, although
defined with different criteria, occurred in 23–72% of the patients, while systemic progression occurred in 23–32%
of the patients [30,33,36]. Accordingly, we reported 22.5% isolated progression, 22.5% oligoprogression and 55%
systemic progression with osimertinib. Two studies showed that systemic progression was associated with a worse
outcome [30,33], whereas in another study mOS was not statistically different between the oligoprogression and
systemic progression groups [36].
Some papers focused on disease progression sites. However, all these studies lacked a control T790M- group; there-
fore an association with the T790M mutation and, similarly, with osimertinib treatment, could not be statistically
established. One study reported lung, CNS, bone and liver as the most frequent disease progression sites in T790M+
patients and CNS, bone and liver as the most frequent metastatic sites [34], while another study confirmed that the
main sites of progression were lung, bone, lymph nodes, brain, pleura and liver [36].
Moreover, in our case series, 39.0% of patients received a local ablative treatment after osimertinib progression
and 29.7% after post-TKI systemic chemotherapy in the T790M- group. Similarly, in published real-world data,
36.8–62% of the patients receiving osimertinib continued the drug beyond disease progression, in association with
a local ablative therapy in 14–69% of patients [34–37,40,41].
Finally, we observed a significantly lower rebiopsy rate for T790M+ patients compared with T790M- patients
after progression on post-TKI systemic therapy. Osimertinib resistance mechanisms have been described for AURA3
and FLAURA patients [44,45]. Consequently, ongoing trials are exploring the application of a personalized therapy
approach even after osimertinib progression [46–49]. This should prompt clinicians to rebiopsy patients even in the
T790M+ setting.
Conclusion
This real-life study confirms the efficacy of osimertinib in the real world when used as a second or further line of
treatment. Thus serial rebiopsy across treatment lines in T790M- patients should be considered. A more limited
progression pattern to post-TKI progression treatment was suggested, although further validation is needed. The
availability and feasibility of postprogression treatment in T790M+ and T790M- patients may impact on OS.
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Summary points
• Real-world data on outcomes of EGFR-mutant Caucasian patients with non-small-cell lung cancer receiving
systemic therapy after failure of early-generation EGFR tyrosine kinase inhibitors are needed.
• This study confirmed the activity and efficacy of osimertinib in the real world in second and further treatment
lines, suggesting the relevance of serial liquid rebiopsy at every disease progression in order to detect EGFR
T790M mutation.
• A lower risk for disease spread was suggested for osimertinib compared with chemotherapy, although further
validation is needed.
• A higher risk of death was reported for patients with T790M negative status, baseline brain and bone metastases
and stable disease or progressive disease as best response to treatment.
• After progression with osimertinib, most T790M-positive patients continued the drug, whereas after progression
with chemotherapy, most T790M-negative patients received a further systemic therapy line.
• The median number of further systemic treatment lines was one in both T790M-positive and T790M-negative
patients.
• A significantly higher proportion of T790M-negative patients underwent rebiopsy compared with T790M-positive
patients.
• Different therapeutic pathways in T790M-positive and T790M-negative patients may impact on overall survival.
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